Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control.

[1]  S. Eschrich,et al.  Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. , 2016, International journal of radiation oncology, biology, physics.

[2]  D. Rades,et al.  Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases , 2016, Radiation oncology.

[3]  M. Duma,et al.  Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. , 2016, International Journal of Radiation Oncology, Biology, Physics.

[4]  Oliver Blanck,et al.  Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  S. Eschrich,et al.  Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes following SBRT. , 2016 .

[6]  Michael Velec,et al.  Accumulated Delivered Dose Response of Stereotactic Body Radiation Therapy for Liver Metastases. , 2015, International journal of radiation oncology, biology, physics.

[7]  B. Loo,et al.  Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. , 2015, International journal of radiation oncology, biology, physics.

[8]  Peter Balter,et al.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. , 2015, The Lancet. Oncology.

[9]  P. Franco,et al.  Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer: a single-institution cohort study. , 2015, International journal of radiation oncology, biology, physics.

[10]  M. Høyer,et al.  Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  I. Poon,et al.  Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[12]  N. Reynaert,et al.  GTV-based prescription in SBRT for lung lesions using advanced dose calculation algorithms , 2014, Radiation oncology.

[13]  S Senan,et al.  2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Matthias Guckenberger,et al.  Support vector machine-based prediction of local tumor control after stereotactic body radiation therapy for early-stage non-small cell lung cancer. , 2014, International journal of radiation oncology, biology, physics.

[15]  Luc Duchateau and Palul Janssen,et al.  The frailty mode , 2013 .

[16]  Matthias Guckenberger,et al.  Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  Federico Rotolo,et al.  parfm: Parametric Frailty Models in R , 2012 .

[18]  B. Kavanagh,et al.  Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases. , 2012, International journal of radiation oncology, biology, physics.

[19]  P. Okunieff,et al.  Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. , 2012, International journal of radiation oncology, biology, physics.

[20]  A. Koong,et al.  Erratum: Stereotactic body radiotherapy for colorectal liver metastases , 2012 .

[21]  L. Brady,et al.  Stereotactic Body Radiation Therapy for Patients with Heavily Pretreated Liver Metastases and Liver Tumors , 2012, Front. Oncol..

[22]  E. Kunieda,et al.  Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  Thomas Lacornerie,et al.  Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? , 2011, International journal of radiation oncology, biology, physics.

[24]  X. Li,et al.  Is α/β for breast cancer really low? , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  B. Kavanagh,et al.  Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control , 2010, Radiation oncology.

[26]  A. Koong,et al.  Stereotactic Body Radiotherapy for Colorectal Liver Metastases: A Pooled Analysis , 2010 .

[27]  A. Wienke.  Frailty Models in Survival Analysis , 2010 .

[28]  F. Esposito,et al.  Adaptation to oxidative stress, chemoresistance, and cell survival. , 2009, Antioxidants & redox signaling.

[29]  Matthias Guckenberger,et al.  Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. , 2009, International journal of radiation oncology, biology, physics.

[30]  A. Gelman.  Scaling regression inputs by dividing by two standard deviations , 2008, Statistics in medicine.

[31]  T. Krieger,et al.  Four-dimensional treatment planning for stereotactic body radiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[32]  U. Haedinger,et al.  Stereotactic radiotherapy of primary liver cancer and hepatic metastases , 2006, Acta oncologica.

[33]  David R. Anderson,et al.  Multimodel Inference , 2004 .

[34]  P. Grambsch,et al.  Penalized Survival Models and Frailty , 2003 .

[35]  U. Kleeberg,et al.  Adjuvant therapy-related shortening of survival (ATRESS): an underrated phenomenon. , 2015, The oncologist.

[36]  Thomas Krieger,et al.  Influence of calculation model on dose distribution in stereotactic radiotherapy for pulmonary targets. , 2005, International journal of radiation oncology, biology, physics.